Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery.

We report a case of cerebral aspergillosis which originated from the sphenoid sinus, and involved a progressive decrease of visual acuity. The neurological signs indicated a cavernous sinus invasion. After extensive intracranial surgery we treated the residual aspergillosis with a high oral dose of itraconazole (800 mg/d for 4 months, followed by 400 mg/d for 5 months). The neurological impairments of the patient gradually subsided with the resolution of the fungal lesion shown on MRI. The successful therapy indicated that itraconazole has a significant role in the treatment of advanced cerebral aspergillosis if it is used in high doses (16 mg/kg/d for adults).

[1]  K. Chapin,et al.  A new classification and diagnostic criteria for invasive fungal sinusitis. , 1997, Archives of otolaryngology--head & neck surgery.

[2]  J. Garau,et al.  Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis? , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Rosenfeld,et al.  Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery--case report and review of the literature. , 1995, Neurosurgery.

[4]  J. Perfect,et al.  NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. , 1994, The American journal of medicine.

[5]  D. Stevens,et al.  Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations , 1993, Antimicrobial Agents and Chemotherapy.

[6]  D. Armstrong,et al.  Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. , 1992, Chemotherapy.

[7]  D. Adams,et al.  10 year review of invasive aspergillosis detected at necropsy. , 1991, Journal of clinical pathology.

[8]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[9]  D. Denning,et al.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. , 1990, Reviews of infectious diseases.

[10]  E. Bailey,et al.  The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole , 1990, Pharmacotherapy.

[11]  E. Bailey,et al.  Erratum: The triazole antifungal agents: A review of itraconazole and fluconazole (Pharmacotherapy (1990) 10 (146-153)) , 1990 .

[12]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[13]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.

[14]  T. Nose,et al.  Intracranial Aspergillus granuloma originating in the sphenoidal sinus--case report. , 1988, Neurologia medico-chirurgica.

[15]  J. Levron,et al.  The pharmacokinetics of itraconazole in animals and man: an overview , 1987 .

[16]  J. Bradley,et al.  Cerebral and orbital Aspergillus infection due to invasive aspergillosis of ethmoid sinus. , 1986, Journal of clinical pathology.